Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
Open Access
- 23 September 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 9 (1), 57
- https://doi.org/10.1186/1475-2840-9-57
Abstract
Background Thiazolidinediones, used for the treatment of patients with type 2 diabetes mellitus (DM2), are associated with an increased incidence of heart failure. We sought to investigate the effects of pioglitazone on novel echocardiographic indices of left ventricular (LV) diastolic function in DM2 patients with LV diastolic dysfunction (LVDD). Methods Eighty-eight asymptomatic DM2 patients on metformin and/or sulfonylureas, aged 64.5 ± 7.7 years, without known cardiovascular disease, with normal LV systolic function and evidence of LVDD were randomly assigned to pioglitazone 30 mg/day (n = 42) or an increase in dose of other oral agents (n = 39) for 6 months. All patients underwent transthoracic conventional and Tissue Doppler Imaging echocardiography at baseline and follow-up. The primary end-point was change in early diastolic velocity of the mitral annulus (E'). Results Improvement of glycaemic control was similar in the 2 groups. A significant difference (p < 0.05) between the 2 groups was found in the treatment-induced changes in fasting insulin, the insulin resistance index HOMA, HDL cholesterol, triglycerides, diastolic blood pressure (all in favor of pioglitazone) and in body weight (increase with pioglitazone). No significant changes were observed in any echocardiographic parameter in either group and did not differ between groups (p = NS for all). E' increased non-significantly and to a similar extent in both groups (p = NS). Conclusions In asymptomatic DM2 patients with LVDD, the addition of pioglitazone to oral conventional treatment for 6 months does not induce any adverse or favorable changes in LV diastolic or systolic function despite improvements in glycaemic control, insulin sensitivity, lipid profile, and blood pressure.Keywords
This publication has 34 references indexed in Scilit:
- Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetesCardiovascular Diabetology, 2009
- Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulationCardiovascular Diabetology, 2009
- Treatment with pioglitazone induced significant, reversible mitral regurgitationCardiovascular Diabetology, 2008
- Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart diseaseDiabetes and Vascular Disease Research, 2008
- Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetesCardiovascular Ultrasound, 2007
- Diabetic Cardiomyopathy RevisitedCirculation, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitusThe American Journal of Cardiology, 2004
- Left‐ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR‐α or ‐γ agonists in a type 2 diabetic animal modelDiabetes/Metabolism Research and Reviews, 2003
- Prognostic importance of systolic and diastolic function after acute myocardial infarctionAmerican Heart Journal, 2003